Literature DB >> 12462423

Methylene Blue--a therapeutic dye for all seasons?

M Wainwright1, K B Crossley.   

Abstract

Since it was first synthesised in 1876, Methylene Blue (MB) has found uses in many different areas of clinical medicine, ranging from dementia to cancer chemotherapy. In addition, MB formed the basis of antimicrobial chemotherapy--particularly in the area of antimalarials--and eventually led to the discovery of the neuroleptic drug families. More recently, the photosensitising potential of MB and its congeners has been recognised, and these are being applied in various antimicrobial fields, especially that of blood disinfection. The range of activities of MB is due to the combination of its simple chemical structure and facility for oxidation-reduction reactions in situ.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12462423     DOI: 10.1179/joc.2002.14.5.431

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  72 in total

Review 1.  Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer's disease.

Authors:  Narendran Annadurai; Khushboo Agrawal; Petr Džubák; Marián Hajdúch; Viswanath Das
Journal:  Cell Mol Life Sci       Date:  2017-06-20       Impact factor: 9.261

2.  Methylene blue inhibits the asexual development of vivax malaria parasites from a region of increasing chloroquine resistance.

Authors:  Rossarin Suwanarusk; Bruce Russell; Alice Ong; Kanlaya Sriprawat; Cindy S Chu; Aung PyaePhyo; Benoit Malleret; François Nosten; Laurent Renia
Journal:  J Antimicrob Chemother       Date:  2014-08-21       Impact factor: 5.790

Review 3.  Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue.

Authors:  Julio C Rojas; Aleksandra K Bruchey; F Gonzalez-Lima
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

4.  Temperature rise during photo-activated disinfection of root canals.

Authors:  B Dickers; L Lamard; A Peremans; S Geerts; M Lamy; M Limme; E Rompen; R J G De Moor; P Mahler; J P Rocca; S Nammour
Journal:  Lasers Med Sci       Date:  2007-12-12       Impact factor: 3.161

Review 5.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

6.  Photodynamic inactivation of Streptococcus mutans and Streptococcus sanguinis biofilms in vitro.

Authors:  Cristiane Aparecida Pereira; Anna Carolina Borges Pereira Costa; Claudia Moura Carreira; Juliana Campos Junqueira; Antonio Olavo Cardoso Jorge
Journal:  Lasers Med Sci       Date:  2012-07-31       Impact factor: 3.161

7.  Photodynamic Therapy for Cancer and for Infections: What Is the Difference?

Authors:  Sulbha K Sharma; Pawel Mroz; Tianhong Dai; Ying-Ying Huang; Tyler G St Denis; Michael R Hamblin
Journal:  Isr J Chem       Date:  2012-09       Impact factor: 3.333

8.  Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation.

Authors:  Alex Crowe; Michael J James; Virginia M-Y Lee; Amos B Smith; John Q Trojanowski; Carlo Ballatore; Kurt R Brunden
Journal:  J Biol Chem       Date:  2013-02-26       Impact factor: 5.157

Review 9.  Photodynamic therapy for localized infections--state of the art.

Authors:  Tianhong Dai; Ying-Ying Huang; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2009 Sep-Dec       Impact factor: 3.631

10.  Biochemical changes in Leishmania braziliensis after photodynamic therapy with methylene blue assessed by the Fourier transform infrared spectroscopy.

Authors:  Kumiko Koibuchi Sakane; Tanmoy Bhattacharjee; Jaciara Fagundes; Luciana Maria Cortez Marcolino; Isabelle Ferreira; Juliana Guerra Pinto; Juliana Ferreira-Strixino
Journal:  Lasers Med Sci       Date:  2020-08-03       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.